DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF

    公开(公告)号:NZ589436A

    公开(公告)日:2012-12-21

    申请号:NZ58943609

    申请日:2009-06-03

    Applicant: ABBOTT LAB

    Abstract: Provided is a binding protein comprising first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first heavy chain variable domain; VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; X1 is a linker with the proviso that it is not CHI; X2 is an Fc region; n is 0 or 1; and wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; X1 is a linker with the proviso that it is not CHI; X2 does not comprise an Fc region; n is 0 or 1; and wherein the binding protein is capable of binding: TNF-alpha and RAGE, wherein the light and heavy chain variable domains have specified sequences. The dual-domain antibodies can be used to treat arthritis and other inflammatory diseases such as colitis, asthma, psoriasis and others.

    INMUNOGLOBULINA CON DOMINIO VARIABLE DUAL

    公开(公告)号:PE20100054A1

    公开(公告)日:2010-03-03

    申请号:PE2009000770

    申请日:2009-06-03

    Applicant: ABBOTT LAB

    Abstract: REFERIDA A UNA PROTEINA DE UNION QUE COMPRENDE UNA CADENA POLIPEPTIDICA VD1-(X1)n-VD2-C-(X2)n, DONDE VD1 ES UN PRIMER DOMINIO VARIABLE DE CADENA PRESADA Y VD2 ES UN SEGUNDO DOMINIO VARIABLE DE CADENA PESADA QUE COMPRENDEN UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE SEQ ID NO: 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54 Y 56; C ES UN DOMINIO CONSTANTE DE LA CADENA PESADA; X1 ES UN CONECTOR, CON LA CONDICION DE QUE NO SEA CH1; X2 ES UNA REGION Fc DE SECUENCIA VARIANTE; n ES 0 O 1. TAMBIEN ESTA REFERIDA A UN VECTOR, UNA CELULA HUESPED, UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHA PROTEINA DE UNION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS AGUDAS Y CRONICAS, CANCER, ENTRE OTRAS

Patent Agency Ranking